New Drug Approvals

Home » APPROVALS 2026 » Venglustat, Ibiglustat

Venglustat, Ibiglustat

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Archives

Categories

Recent Posts

Blog Stats

  • 5,110,320 hits

Unknown's avatar

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.7K other subscribers

add to any

Share

Venglustat, Ibiglustat

CAS 1401090-53-6

C20H24FN3O2S, 389.5 g/mol

CAS 1629063-78-0, Ibiglustat L-malate, Venglustat malate, C24H30FN3O7S, 523.6 g/mol

Infilbray, APPROVALS 2026, FDA 2026, Genz-682452, GZ/SAR402671, BLP1XA3FZA, SAR-402671, SAR 402671, Genz-682452-AA, BLP1XA3FZA, GZ402671, WHO 10063, Ibiglustat L-malate, Venglustat malate

[(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate

To treat the neurological symptoms of Type 3 Gaucher disease

Venglustat, sold under the brand name Infilbray, is a medication used for the treatment of Gaucher disease.[1] It is a glucosylceramide synthase inhibitor.[1] It is used as the salt venglustat malate.[1] It is given by mouth.[1]

The most common side effects of venglustat include gastrointestinal symptoms as well as adverse effects on mood.[2]

Venglustat was approved for medical use in the United States in November 2026.[2]

Medical uses

Venglustat indicated for the treatment of neurological manifestations of type 3 Gaucher disease in people weighing at least 15 kg (33 lb).[1]

Venglustat crosses the blood-brain barrier to reduce the accumulation of harmful substances in the body and brain.[2]

Type 3 Gaucher disease is a rare, inherited condition in which the body cannot properly break down fatty substances, called glucosphingolipids, due to a deficient or malfunctioning enzyme.[2]

Adverse effects

The most common side effects of venglustat include gastrointestinal symptoms as well as adverse effects on mood.[2]

Serious psychiatric risks, including suicidal ideation and behavior, have been reported.[2] Potential risks identified from animal studies include potential clouding of vision in younger people and adverse effects on fetal development when it is taken during pregnancy.[2]

History

The US Food and Drug Administration approved venglustat supported by data from a randomized, double-blind, multi-center clinical study enrolling 43 participants aged 12 years and older with type 3 Gaucher disease who had previously been treated with enzyme replacement therapy and had achieved systemic disease stabilization.[2] Participants received either venglustat orally once daily or intravenous enzyme replacement therapy every two weeks for 52 weeks.[2] Treatment effectiveness was evaluated using two assessments that capture the neurological symptoms central to daily life in participants with type 3 Gaucher disease, including those related to ataxia (loss of muscle control and coordination) and cognitive function.[2] At Week 52, participants treated with venglustat demonstrated improvement on a measure that combined both assessments compared to those taking enzyme replacement therapy for the treatment of non-neurologic manifestations of type 3 Gaucher disease.[2]

Society and culture

Venglustat was approved for medical use in the United States in November 2026.[3]

The US Food and Drug Administration (FDA) granted the application for venglustat, breakthrough therapy, rare pediatric disease, fast track, orphan drug, and priority review designations.[2][3] The FDA granted the approval of Infilbray to Genzyme Corporation.[2]

Names

Venglustat is the international nonproprietary name.[4]

Venglustat is sold under the brand name Infilbray.[2][3]

SYN

SYN

WO2020/163244, 2020,

Organic Process Research and Development, 2015, vol. 19, V 5, PG 576 – 581

Journal of Medicinal Chemistry, 2023, vol. 66, V 2, PG1601 – 1615

PAT

WO2012129084 – GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012129084&_cid=P12-MWR8EI-85348-1

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

str1

AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

……

References

  1. “Infilbray FDA label” (PDF). products.sanofi.us.
  2. “FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease” (Press release). FDA. 18 November 2026. Retrieved 19 November 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  3. “Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease”. Sanofi (Press release). 18 November 2026. Retrieved 19 November 2026.
  4. World Health Organization (2016). “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76”. WHO Drug Information. 30 (3). hdl:10665/331020.

Further reading

  • Bhattiprolu M, Kappler M, Han TU, Henderson M, Serlin Y, Sidransky E (May 2026). “Pharmacotherapies for Gaucher disease: what’s new on the horizon?”. Expert Opinion on Pharmacotherapy. 27 (7): 585–597. doi:10.1080/14656566.2026.2667325. PMID 42153355.
Clinical data
Trade namesInfilbray
AHFS/Drugs.comInfilbray
License dataUS DailyMed: Venglustat
Routes of
administration
By mouth
Drug classGlucosylceramide synthase inhibitor
ATC codeNone
Legal status
Legal statusUS: ℞-only[1]
Identifiers
IUPAC name
CAS Number1401090-53-61629063-78-0
PubChem CID6019924260199241
IUPHAR/BPS11550
DrugBankDB14966
ChemSpider34989426
UNIIBLP1XA3FZA94855LQZ8D
KEGGD11633D11634
ChEBICHEBI:757083
ChEMBLChEMBL4297611ChEMBL4594270
PDB ligandKYF (PDBe, RCSB PDB)
Chemical and physical data
FormulaC20H24FN3O2S
Molar mass389.49 g·mol−1
3D model (JSmol)Interactive imageInteractive image
SMILES
InChI

PAT

////////venglustat, ANAX LABS, Infilbray, APPROVALS 2026, FDA 2026, Genz-682452, GZ/SAR402671, BLP1XA3FZA, SAR-402671, SAR 402671, Genz-682452-AA, BLP1XA3FZA, GZ402671, WHO 10063, Ibiglustat L-malate, Venglustat malate

#venglustat, #ANAX LABS, #Infilbray, #APPROVALS 2026, #FDA 2026, #Genz-682452, #GZ/SAR402671, #BLP1XA3FZA, #SAR-402671, #SAR 402671, #Genz-682452-AA, #BLP1XA3FZA, #GZ402671, #WHO 10063, #Ibiglustat L-malate, #Venglustat malate


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.7K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

View Full Profile →

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.